BioStem Technologies, Inc. (BSEM) Form S-1 — Oct 2, 2026
BioStem Technologies filed an S-1 registering the resale of up to 2,224,270 shares by selling stockholders, tied to a September 29, 2026 private placement of 735,296 shares at $4.08 per share plus Series A and Series B warrants (exercise price $3.83) and 18,382 placement agent warrants at $6.12. The company receives no proceeds from the resale, only potential cash from future warrant exercises. The prospectus discloses substantial doubt about BioStem's ability to continue as a going concern, citing its accumulated deficit, expected ongoing losses, and the unpaid $10.0 million BioTissue Clearance Payment that was due September 15, 2026.
Key figures
- Shares Offered
- 2224270
- Shares Outstanding
- 18672125
- Net loss fy2025
- $6.6 million
- Cef facility size
- $40,000,000
- Cef commitment fee
- $400,000
- Accumulated deficit
- $21.2 million
- Clearance payment owed
- $10.0 million
- Closing price oct 1 2026
- 3.07
- May 2026 placement price
- 3.35
- Common warrant exercise price
- 3.83
- Placement agent warrant shares
- 18382
- May 2026 placement gross proceeds
- $2.5 million
- Private placement price per share
- 4.08
- Pro forma revenue six months 2026
- 15521105
- Shares underlying series a warrants
- 735296
- Shares underlying series b warrants
- 735296
- Placement agent warrant exercise price
- 6.12
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.